| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Adult |
| State: | Solid |
| Purity: | >98% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
Product Name: Febuxostat
Synonyms: FEBUXOSTAT;Tei-6720;2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid;2-[3-Cyano-4-isobutoxyphenyl]-4-methylthiazole-5-carboxylic acid;2-(3-Cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic Acid;2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methyl-5-thiazolecarboxylic Acid;TMX 67;Febuxosta
CAS: 144060-53-7
MF: C16H16N2O3S
MW: 316.37
Product Categories: Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;zjh;API;Febuxostat;TRILIPIX;Other APIs;eterocycles
Febuxostat was discovered by scientists at the Japanese pharmaceutical company Teijin in 1998. Teijin partnered the drug with TAP Pharmaceuticals in the US and Ipsen in Europe. Ipsen obtained marketing approval for febuxostat from the European Medicines Agency in April 2008, Takeda obtained FDA approval in February 2009, and Teijin obtained approval from the Japanese Pharmaceuticals and Medical Devices Agency in 2011.
Gout is a heterogeneous group of diseases, hereditary or acquired due to uric acid excretion decreasing and purine metabolism. Because the body produces too much uric acid and renal clearance capacity decreases, uric acid accumulates in the body, leading to urate crystals deposited in the joints and organs. Therefore, it means the treatment of gout usually taken to be: promote uric acid excretion, and suppression of uric acid, and adopt appropriate measures to improve related symptoms.
Uric acid formation is associated with purine metabolism, in the final step of purine metabolism, hypoxanthine becomes xanthine through the role of xanthine oxidoreductase (XOR) ,then further generate uric acid ,inhibiting activity of the enzyme can effectively reduce uric acid production. Febuxostat is currently the world's latest generation of non-purine selective inhibitor of xanthine oxidase, which acts highly selectively on the oxidase, then reduces uric acid synthesis, reduces uric acid levels, thus effectively treats ventilation diseases.
| Items of analysis | specification | results |
| Appearance: | white to off-white crystalline powder | white crystalline powder |
| Identification | A.HPLC | Conforms |
| B.UV | Conforms | |
| Total impurites: | NMT 0.5% | 0.10% |
| Any maximum impurity: | NMT 0.1% | 0.03% |
| Ethanol: | NMT 0.5% | ND |
| DMF: | NMT 0.088% | ND |
| Loss on Drying: | Not more than 1.0% | 0.22% |
| Residue on ignition: | Not more than 0.1% | 0.05% |
| Heavy Metals : | Not more than 20ppm | Conforms |
| Chlorides: | Not more than 0.04% | Conforms |
| Assay(on dried basis) | Not less than 98.5% | 100.2% |
| conclusion: | qualified | |
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}